Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics

Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics

Thumbnail Image
Download
Name

Kugelman-2015-Evaluation of the po.pdf

Size

601.77 KB

Format

Adobe PDF

Checksum (MD5)

bb4d57d07eb0ece67bef38c09efcceb5

Author(s)
Kugelman, Jeffrey R.
•
Sanchez-Lockhart, Mariano
•
Andersen, Kristian G.
•
Gire, Stephen
•
Park, Daniel J.
•
Lin, Aaron E.
•
Wohl, Shirlee
•
Sabeti, Pardis C.
•
Kuhn, Jens H.
•
Palacios, Gustavo F.
more
Date Issued
January 2015
Journal
mBio
Publisher
American Society for Microbiology
Citation
Kugelman, Jeffrey R., Mariano Sanchez-Lockhart, Kristian G. Andersen, Stephen Gire, Daniel J. Park, Rachel Sealfon, Aaron E. Lin, et al. “Evaluation of the Potential Impact of Ebola Virus Genomic Drift on the Efficacy of Sequence-Based Candidate Therapeutics.” mBio 6, no. 1 (January 20, 2015): e02227–14.
Version
Author's final manuscript
Abstract
Until recently, Ebola virus (EBOV) was a rarely encountered human pathogen that caused disease among small populations with extraordinarily high lethality. At the end of 2013, EBOV initiated an unprecedented disease outbreak in West Africa that is still ongoing and has already caused thousands of deaths. Recent studies revealed the genomic changes this particular EBOV variant undergoes over time during human-to-human transmission. Here we highlight the genomic changes that might negatively impact the efficacy of currently available EBOV sequence-based candidate therapeutics, such as small interfering RNAs (siRNAs), phosphorodiamidate morpholino oligomers (PMOs), and antibodies. Ten of the observed mutations modify the sequence of the binding sites of monoclonal antibody (MAb) 13F6, MAb 1H3, MAb 6D8, MAb 13C6, and siRNA EK-1, VP24, and VP35 targets and might influence the binding efficacy of the sequence-based therapeutics, suggesting that their efficacy should be reevaluated against the currently circulating strain.
MIT Department
Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Terms of Use
Creative Commons Attribution
http://creativecommons.org/licenses/by-nc-sa/3.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/94325
DOI of Published Version
https://doi.org/10.1128/mBio.02227-14
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.